Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials-Reference-Cited by-同舟云学术

Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials

Published:2017-02-24 Issue:4 Volume:23 Page:547-555
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Tiede A.¹^ORCID,Abdul-Karim F.²,Carcao M.³^ORCID,Persson P.⁴,Clausen W. H. O.⁴,Kearney S.⁵,Matsushita T.⁶,Negrier C.⁷,Oldenburg J.⁸,Santagostino E.⁹,Young G.¹⁰

Affiliation:

1. Clinic for Haematology, Haemostaseology, Oncology and Stem Cell Transplantation; Hannover Medical School; Hannover Germany

2. Hemophilia Clinic; National Blood Centre; Wilayah Persekutuan Kuala Lumpur Malaysia

3. Division of Haematology/Oncology; Department of Paediatrics; Child Health Evaluative Sciences; Research Institute; The Hospital for Sick Children; University of Toronto; Toronto ON Canada

4. Novo Nordisk A/S; Søborg Denmark

5. CHCMN Hemophilia and Thrombosis Center; Children's Hospital and Clinics of Minnesota; MN USA

6. Department of Transfusion Medicine; Nagoya University Hospital; Nagoya Japan

7. Centre Regional de Traitement de l'Hemophilie; Hopital Louis Pradel; University Claude Bernard; Lyon France

8. Institute of Experimental Haematology and Transfusion Medicine; Bonn Germany

9. Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre; Maggiore Hospital; IRCCS Ca Granda Foundation; Milan Italy

10. Hemostasis and Thrombosis Center; Children's Hospital Los Angeles; Keck School of Medicine; University of Southern California; Los Angeles CA USA

Funder

Novo Nordisk

Bayer

Baxalta

Biogen Idec